$HYPR

Lucid Capital Markets initiated coverage on Hyperfine Inc. (NASDAQ:HYPR) with a buy rating and $2.00 price target, citing its innovative Swoop MRI system and growth potential. The stock trades near its 52-week low at $0.72. Hyperfine reported Q2 2026 revenue of $3.9M, up 45% YoY but below estimates, with adjusted losses meeting expectations. The company has over 200 systems deployed globally and recently received FDA clearance for its Optive AI software update.

Hyperfine, Inc. (HYPR) received CE and UKCA approvals for its Optive AI software update, improving image quality and workflow for the Swoop Model 2 portable brain MRI, aiding European adoption.

Hyperfine (HYPR) received CE and UKCA approvals for its Optive AI software, enhancing the Swoop system's imaging capabilities. The company is supporting 'Notes and Neurons,' a German initiative combining music and brain health research using the Swoop system for live brain imaging. Hyperfine aims to expand the Swoop system's use in brain health applications, with ongoing rollout in four international markets.

Hyperfine (HYPR) reported preliminary Q3 revenue of $6.0M, exceeding the consensus estimate of $5.13M. This marks a 53% sequential increase from Q2 2026. The company's shares rose nearly 9% in pre-market trading.

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

Hyperfine, Inc. (HYPR) generates 83.4% of revenue from DEVICE sales, with a gross margin of 50.72% but negative operating and net margins. It competes with SKIN and ECOR, with a market cap of $88.36M. Investors assess its performance in the Advanced Medical Equipment & Technology industry.

Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered

Hyperfine (Nasdaq: HYPR) says it has started launching its next-generation Swoop portable MRI system (Model 2) in Europe after CE mark and UKCA approval. The company also reports Model 2 inclusion in UniHA’s procurement listing for France’s public hospitals and plans broader European availability via distribution partners in 2026.

HALE BRETT (CFO and CAO) sold 6,047 shares of Hyperfine, Inc. (HYPR) at $1.65 on 2026-05-26.